SystImmune and Bristol Myers Squibb announce encouraging interim Phase III data for izalontamab brengitecan (Iza-bren) in previously treated metastatic triple-negative breast cancer (TNBC), highlighting potential improvements in patient outcomes. SystImmune, Inc. and Bristol Myers Squibb have announced positive topline results…
Kairos Pharma, Ltd. moves to expand its oncology pipeline with the proposed acquisition of two clinical-stage NSCLC assets from Celyn Therapeutics, Inc., strengthening its position in innovative cancer therapeutics. Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company dedicated to advancing innovative…
The U.S. Food and Drug Administration sets a PDUFA target date of June 30, 2026, accelerating review of olezarsen for patients with severe hypertriglyceridemia. Ionis Pharmaceuticals, Inc. has announced a major regulatory milestone in its efforts to address severe hypertriglyceridemia…
Evox Therapeutics Ltd collaborates with Rett Syndrome Research Trust to evaluate its ExoEdit® exosome-based platform for developing a potential gene editing therapy targeting Rett syndrome. Evox Therapeutics Ltd has announced a new strategic collaboration with the Rett Syndrome Research Trust…
IonQ Deploys One of Europe’s Most Advanced Quantum Key Distribution Networks to Strengthen Secure Communications Infrastructure IonQ , a leading quantum computing and networking company, has announced the successful deployment of the technology powering the Romanian National Quantum Communication Infrastructure…
Asahi Kasei expands into severe infectious diseases with the €780 million acquisition of AiCuris Anti-infective Cures AG, strengthening its specialty pharmaceutical pipeline and global growth strategy. Asahi Kasei has entered into a definitive agreement to acquire all issued shares of…
Arima Genomics Study Highlights Power of Whole-Genome Rearrangement Detection in Lymphoid Cancers Arima Genomics, Inc., a biotechnology company focused on leveraging whole-genome sequence and structural information to deliver comprehensive insights for cancer therapy selection, has announced the publication of a…
Royalty Pharma Names Kenneth Sun as Senior Vice President and Head of Asia, Strengthening Its Global Expansion Strategy and Regional Presence Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Kenneth Sun as Senior Vice President and Head of…
Wisdom Bioscience Establishes Scientific Advisory Board to Advance Oral Cancer Diagnostics and Screening Wisdom Bioscience, a biotechnology company revolutionizing oral cancer diagnostics, has announced the formation of its Scientific Advisory Board (SAB) following a successful initial funding round. The SAB…
Roche’s fenebrutinib reaffirms potential as the sole BTK inhibitor for relapsing and primary progressive MS with positive FENhance 1 Phase III results. Roche announced today that the pivotal Phase III study (FENhance 1) of fenebrutinib in RMS met its primary…